Press release
Investigation announced for Investors who lost money with shares of Senti Biosciences, Inc. (NASDAQ: SNTI)
An investigation for investors in Senti Biosciences, Inc. (NASDAQ: SNTI) shares over potential securities laws violations.
Investors who purchased shares of Senti Biosciences, Inc. (NASDAQ: SNTI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Senti Biosciences, Inc. (NASDAQ: SNTI) concerning whether a series of statements by Senti Biosciences, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 25, 2021, Dynamics Special Purpose Corp. (NASDAQ: DYNS) held its initial public offering (IPO) at $10.00 per share and raised $200 million.
Then on December 20, 2021, Dynamics Special Purpose Corp announced it was engaging in a $601 million de-SPAC transaction with Senti Biosciences, Inc.
The transaction closed on June 8, 2022 and the combined company was renamed Senti Biosciences, Inc. (NASDAQ: SNTI).
Shares of Senti Biosciences, Inc. (NASDAQ: SNTI) declined to as low as $0.271 per share on April 22, 2024.
Those who purchased shares of Senti Biosciences, Inc. (NASDAQ: SNTI) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Senti Biosciences, Inc. (NASDAQ: SNTI) here
News-ID: 3496690 • Views: …
More Releases from Shareholders Foundation, Inc.
NASDAQ: REPL Investor Alert: Lawsuit against Replimune Group, Inc. seeks to reco …
An investor, who purchased shares of Replimune Group, Inc. (NASDAQ: REPL), filed a lawsuit over alleged violations of Federal Securities Laws by Replimune Group, Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NASDAQ: REPL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
NYSE: BMI Long Term Investor Alert: Investigation over potential Wrongdoing by c …
An investigation was announced for long-term investors in shares of Badger Meter, Inc. (NYSE: BMI) concerning potential breaches of fiduciary duties by certain directors of Badger Meter, Inc. was announced.
Investors who are current long term investors in Badger Meter, Inc. (NYSE: BMI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit Alert: Investors who lost money with ARS Pharmaceuticals, Inc. (NASDAQ: …
An investor, who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), filed a lawsuit over alleged violations of Federal Securities Laws by ARS Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NASDAQ: SPRY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation Alert: Investors in GeneDx Holdings Corp. (NASDAQ: WGS) should con …
An investigation was announced for current long-term investors in shares of GeneDx Holdings Corp. (NASDAQ: WGS) concerning potential breaches of fiduciary duties by certain directors and officers of GeneDx Holdings Corp.
Investors who are current long term investors in GeneDx Holdings Corp. (NASDAQ: WGS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
More Releases for Senti
Acute Myeloid Leukemia Pipeline Development Outlook Report 2025: Novel Targets, …
DelveInsight's "Acute Myeloid Leukemia Pipeline Insights 2025" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Acute Myeloid Leukemia Pipeline Drugs Report 2025 by DelveInsight: Examining Dru …
DelveInsight's "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
NK Cell Therapy Market Poised for Transformative Growth by 2034: Insights on Cli …
DelveInsight has released its latest market analysis report titled "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034", delivering a comprehensive view of the evolving therapeutic landscape of Natural Killer (NK) cell therapy across the 7 Major Markets (7MM) - the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The report provides an in-depth understanding of current treatment practices, emerging NK cell therapies, market size trends, clinical…
Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
NK Cell Therapy Therapeutics Market Size in 7MM is expected to grow at a decent …
DelveInsight's "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the NK Cell Therapy, historical and forecasted epidemiology as well as the NK Cells therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the NK Cell Therapy Market Share @ NK Cell Therapy Market Outlook- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Me …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive…
